Vascular regeneration using autologous mesenchymal stem cells for peripheral arterial disease
- Conditions
- Peripheral Arterial Disease (Fontaine stages three and four)
- Registration Number
- JPRN-UMIN000009943
- Lead Sponsor
- Rogenkai Welfare Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Not provided
(1)The patient of hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) infection, and adult T-cell leukemia (2)The hypersensitivity to a cow or pig origin protein, the patient that has the past of side effects (3)The patient showing severe cardiac failure evidenced by cardiac echo examination. (4)Malignant diseases. (5)High-risk retinopathy (6)Serious problems of liver and renal function (7)Interstitial pneumonia. (8)Blood diseases such as anemia and leykocytosis. (9)A pregnant woman, a nursing mother, the patient that may have become pregnant, the female patient who is planning pregnancy by the end of this treatment term. (10)In addition, the patient whom the principal investigator or the researcher judged to be unsuitable based on the medical rationale
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ABI(Ankle Brechial Pressure Index): 7days, 1,6 and 12 months post transplantation. Angiography : 12 months post transplantation.
- Secondary Outcome Measures
Name Time Method Walking time without pain using tredmil: 1, 6 and 12 months post transplantation